Toxicity affects all facets of biological research and drug development. A guiding tenet in toxicity studies is to eliminate toxic compounds as early as possible in the drug development process. Organ-specific toxicity testing is of chief importance because drug-induced toxicities in various organs are the leading cause of drug failure. Multiplex toxicity assays enable researchers to simultaneously measure multiple toxicity biomarkers for various organs to gain a better understanding of drug-induced toxicity. Learn how MILLIPLEX® multiplex toxicity assays are advancing research on liver injury, kidney toxicity, and more.
The ideal toxicity biomarkers are not only organ- or tissue-specific but are also sensitive enough to identify organ or tissue damage before it becomes too extensive. The Predictive Safety Testing Consortium (PSTC) identified and qualified several protein biomarkers that may better predict organ-specific toxicity, and regulatory agencies have recommended assay characteristics for establishing toxicity. Furthermore, toxicity biomarkers should ideally apply to preclinical models in which early safety is frequently assessed.
In addition to regulatory requirements in drug development, endocrine disruptor chemical (EDC) testing has been mandated by environmental regulatory agencies worldwide. New chemical entities, and even older pesticides, environmental chemicals, and food additives, are required to be tested for their capacity to disrupt human and animal developmental and reproductive health.
Bead-based multiplex toxicity assays enable a precise, multiparametric analysis of toxicity and its underlying processes. MILLIPLEX® multiplex toxicity biomarker assay kits enable researchers to simultaneously quantify dozens of toxicity analytes across several species (including rat, mouse, porcine, canine, and feline models). For example, these assays can analyze specific toxicities including:
Based on Luminex® xMAP® technology, our analytically verified assay kits provide:
Explore our popular MILLIPLEX® multiplex toxicity assays below.
Detecting qualified kidney toxicity biomarkers, in contrast to traditional BUN and serum creatinine (SCr) tests, can enable early detection and localization of kidney damage, which are crucial for the accurate assessment of toxicity.
Biomarkers like ARG1 and SDH are hepatocellular and hepatobiliary enzymes that are released into circulation upon the occurrence of liver injury.
In addition to heart rate and mean arterial blood pressure, measuring key proteins in smooth muscle, endothelial cells, and immune-mediated cells may yield promising biomarkers for vascular injury.
Reproductive, adrenal, thyroid, and pituitary hormone levels and their functions in humans and animals can be altered with exposure to EDCs. In vitro cell assays and in vivo models for various species may be used to assess the effects of chemical exposure.
Genotoxicity assays help researchers assess the effects of DNA damage.
For Research Use Only. Not For Use In Diagnostic Procedures.